Hetero, Cipla get gesture to make, market antiviral medication remdesivir Kumar Jeetendra | June 21, 2020 India’s Drug Regulator on June 20 allowed to Hetero and Cipla to produce and market antiviral medication remdesivir for “confined crisis use” on hospitalized COVID-19 patients, official sources said. This comes a day after the Drug Controller General of India (DCGI), thinking about the crisis and neglected requirement for medications considering the coronavirus episode, allowed …
Sanofi eyes endorsement of COVID-19 immunization by first 50% of 2021 Kumar Jeetendra | June 23, 2020 French drugmaker Sanofi SA, said on June 23, it hopes to get endorsement for the potential COVID-19 antibody it is creating with Britain’s GlaxoSmithKline Plc by the primary portion of one year from now, quicker than recently envisioned. Sanofi, which is facilitating a virtual innovative work occasion, and GSK had said in April the immunization, …
S Africa starts mainland’s first preliminaries for COVID-19 antibody Kumar Jeetendra | June 25, 2020 An inhabitant from the rambling Black township of Soweto, south of here, has gotten the principal South African to be infused with a preliminary immunization for COVID-19 as researchers look for a treatment for the infection which has tainted millions and slaughtered several thousands over the globe. Mhlongo (24), is one of around 2,000 South …
India’s first COVID-19 immunization ‘COVAXIN’ by Bharat Biotech gets DCGI endorsement for human trial Kumar Jeetendra | June 30, 2020 India’s very first vaccine candidate against the novel coronavirus, COVAXIN, has received a nod in the Drug Controller General of India (DCGI) for further clinical trials Stage I and two in infected men and women. The vaccine is under development by Hyderbad-based biotechnology firm Bharat Biotech in cooperation with the Indian Council of Medical Research …
Indonesia looking for its own COVID-19 immunization in the midst of stress over access Kumar Jeetendra | July 2, 2020 Indonesia has been operating to produce its COVID-19 vaccine following year, thanks to growing anxiety that developing nations could have trouble getting access to a future jab, the head of Indonesia’s national COVID-19 research staff said Thursday. “The production capability and ability of biotech businesses in the world is, we understand, limited, and global supply …
ICMR affirms Covaxin dispatch likely by August 15, clinical preliminaries optimized Kumar Jeetendra | July 3, 2020 An ICMR representative has affirmed the credibility of a letter by ICMR Head that said the antibody preliminaries for Hyderabad-based Bharat Biotech’s COVID-19 immunization Covaxin have been optimized and that it could be propelled most recent by August 15. ICMR had on July 2 purportedly asked Bharat Biotech in an inner correspondence to quick track …
China’s Sinovac begins late stage preliminaries for its COVID-19 antibody Kumar Jeetendra | July 7, 2020 China’s Sinovac Biotech is starting Phase III trials of its potential coronavirus vaccine in Brazil, ” said on Monday, becoming among three companies to transfer to the late stages at the race to develop an inoculation against the disorder. It follows a fast-track approval for the trials by Brazilian labs last week. Sinovac stated the …
Researchers distinguish aggravates that square replication of COVID-19 infection Kumar Jeetendra | July 12, 2020 Whilst the death toll from the COVID-19 pandemic mounts, the boffins worldwide carry on their push to create effective treatments and a vaccine to its highly infectious respiratory tract. The inhibitors demonstrate potent structural and chemical connections with an viral critical to this herpes virus’s capacity to proliferate. The very promising drug candidates – like …
Oxford Covid antibody beginning phase preliminary shows promise Kumar Jeetendra | July 17, 2020 London, A Covid-19 vaccine manufactured by researchers at Oxford University generated an immune response from the disease in Phase-1 trial,” The Telegraph reported even as official book of those answers are awaited. Even the Oxford vaccine candidate is believed to be contributing the race among over 100 to obtain a successful protection against the disorder. …
Phase 2 preliminary discovers Chinese COVID-19 antibody is sheltered, incites insusceptible reaction: Lancet study Kumar Jeetendra | July 21, 2020 A phase II clinical trial of a COVID-19 vaccine candidate, conducted in China, has found it is safe and causes an immune reaction, a study published in The Lancet says. Researchers, for example those from the Center for Disease Control and Prevention, said the trial sought to assess the safety and immunogenicity of this vaccine …
Russia delivers first group of Sputnik V for open: Report Kumar Jeetendra | September 8, 2020 Russia has released the first batch of COVID-19 vaccine, called Sputnik V, into civil movement and the supplies of the medication to the Russian regions are expected soon, said a report citing Russian Health Ministry. The Russian health ministry enrolled the first vaccine against COVID-19, developed by Gamaleya National Research Center of Epidemiology and Microbiology …
Bharat Biotech requested to submit total phase 2 information of its COVID-19 antibody before ph 3 preliminary Kumar Jeetendra | October 10, 2020 According to officials, the Hyderabad-based vaccine manufacturer applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to run phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate. The firm in its program said that the study would cover 28,500 subjects aged 18 years and above and would …
